Do these 3 things before closing this tab:
1Fix the driver behind crashes, sound loss and screen glitches2Repair Windows errors before they cause bigger problems3Scan for outdated or missing drivers - takes under a minuteSome observational studies have found that antidepressant use is associated with survival differences in particular cancer groups, but the results are mixed and do not show that these medicines cause people to live longer. A 2026 meeting abstract, for example, found no overall-survival difference associated with baseline SSRI/SNRI use among lung-cancer patients receiving immunotherapy. Antidepressants should not be used as cancer treatments; decisions about treating depression are separate and should be made with a clinician.
What the studies say about antidepressants and cancer survival
The available findings differ by cancer, medication class, when use was measured, and the outcome studied. They are mostly observational: researchers compare groups based on medication use rather than randomly assigning antidepressants as cancer treatment. Differences between patients or their care may therefore help explain an observed association.
As an Amazon Associate I earn from qualifying purchases.
| Study and population | Exposure and outcome | Finding | What it can establish |
|---|---|---|---|
| 2017 NCI-Maryland lung-cancer study; 1,097 patients | Antidepressant use and lung-cancer-specific survival | Use was associated with longer cancer-specific survival. Class-specific analyses reported associations for norepinephrine and dopamine reuptake inhibitors (NDRIs) and tricyclic antidepressants (TCAs). | It reports associations in this study population, not proof that medication caused longer survival. |
| 2026 ASCO meeting abstract; propensity-matched real-world cohort of lung-cancer patients receiving immune-checkpoint inhibitors | Baseline SSRI/SNRI use and overall survival | Median overall survival was 671 days with baseline use versus 665 days without; HR 1.01 (95% CI 0.97–1.04). | The abstract reported no overall-survival difference. It is observational, not a randomized test of antidepressants as cancer therapy. |
| 2023 JAMA Network Open hepatocellular-carcinoma cohort; sample size not stated in the reported findings | Antidepressant use before or after diagnosis and mortality | Use before diagnosis was not associated with lower cancer-specific mortality after adjustment (HR 1.06, 95% CI 0.96–1.17). Use after diagnosis was associated with lower overall and cancer-specific mortality; effect estimates are not stated here. | The different before- and after-diagnosis findings are observational and do not establish a medication effect. |
Why the lung-cancer findings are not a contradiction to resolve by choosing a winner
The 2017 study examined lung-cancer-specific survival and reported class-specific associations for NDRIs and TCAs. The 2026 abstract examined baseline SSRI/SNRI use in patients receiving immune-checkpoint inhibitors and reported overall survival. These are different drug classes, populations, exposure definitions, and endpoints. Neither result establishes that antidepressants are interchangeable or that any class treats lung cancer.
Why timing matters in the liver-cancer cohort
The hepatocellular-carcinoma study found no adjusted association between use before diagnosis and lower cancer-specific mortality, but reported lower mortality associated with use after diagnosis. Postdiagnosis medication use can be related to factors such as patients’ health, treatment, or access to care. Because this was not a randomized comparison, the association cannot show that starting an antidepressant after diagnosis lowers mortality.
Depression care and cancer treatment answer different questions
Antidepressants may be prescribed to treat depression in people with cancer, but evidence about depression symptoms is not evidence that a medicine treats a tumor or extends survival. A 2023 Cochrane review covered 14 studies and 1,364 participants. It concluded that antidepressants may reduce depressive symptoms over six to 12 weeks, while rating the evidence very low certainty. The review did not establish a cancer-survival benefit and said use should be considered individually.
Depression itself has also been studied in relation to survival. A 2021 study of 20,582 people with breast, colorectal, gynecological, lung, or prostate cancer found that major depression was associated with worse survival across those cancer groups; the pooled hazard ratio was 1.41 (95% CI 1.29–1.54). That association does not show that antidepressants reverse the risk or improve cancer outcomes. The mechanisms and clinical implications require further study.
Rank #2
How to read a claim about antidepressants and cancer
Before applying a study result to a patient, check what was actually compared. A headline about “survival” can hide major differences in the evidence:
- Cancer and patient group: Results from one cancer type, treatment setting, or stage should not automatically be applied to another.
- Medication class: SSRIs, SNRIs, NDRIs, and TCAs are distinct classes. An association for one does not establish a benefit for another.
- Timing: Use before diagnosis and use after diagnosis are different exposures, as the hepatocellular-carcinoma findings illustrate.
- Outcome: Overall survival, cancer-specific survival, and improvement in depressive symptoms are not interchangeable measures.
- Study design and uncertainty: Cohort studies and real-world analyses can identify associations, but they cannot by themselves establish cause and effect. Confidence intervals also matter: the 2026 abstract’s HR of 1.01 had a 95% CI of 0.97–1.04.
What to do if you have cancer and take—or are considering—an antidepressant
Do not start, stop, or change an antidepressant to try to affect cancer survival. Discuss depression symptoms and medication decisions with the treating clinician, who can consider the person’s needs and overall care. The Cochrane review’s conclusion was that “The use of antidepressants in people with cancer should be considered on an individual basis.”
Quick Recap
Best Value
Rank #3
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
